CINECA IRIS Institutional Research Information System

ORLANDI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.388
EU - Europa 2.733
AS - Asia 2.585
SA - Sud America 388
AF - Africa 145
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 13.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.234
IT - Italia 873
CN - Cina 797
SG - Singapore 782
HK - Hong Kong 470
DE - Germania 461
SE - Svezia 434
BR - Brasile 334
BG - Bulgaria 188
GB - Regno Unito 184
VN - Vietnam 141
FI - Finlandia 126
CA - Canada 119
TR - Turchia 98
FR - Francia 83
RU - Federazione Russa 82
IN - India 76
UA - Ucraina 71
CI - Costa d'Avorio 67
AT - Austria 59
JP - Giappone 39
KR - Corea 35
BE - Belgio 27
PL - Polonia 27
CH - Svizzera 26
NG - Nigeria 25
BD - Bangladesh 24
NL - Olanda 19
SN - Senegal 18
AR - Argentina 16
MX - Messico 16
ID - Indonesia 14
PK - Pakistan 14
IQ - Iraq 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 11
EC - Ecuador 11
CO - Colombia 10
ES - Italia 10
MA - Marocco 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
PH - Filippine 9
VE - Venezuela 9
AU - Australia 8
DK - Danimarca 8
LT - Lituania 8
IR - Iran 7
GR - Grecia 5
IE - Irlanda 5
JO - Giordania 5
CR - Costa Rica 4
HU - Ungheria 4
NO - Norvegia 4
PS - Palestinian Territory 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
BB - Barbados 3
BJ - Benin 3
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
LB - Libano 3
NP - Nepal 3
PY - Paraguay 3
RO - Romania 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BH - Bahrain 2
CL - Cile 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
Totale 13.245
Salva come PNG Salva come JPEG
Città #
Woodbridge 833
Ashburn 765
Fairfield 612
Ann Arbor 603
Hong Kong 466
Dallas 464
Houston 459
Chandler 458
Singapore 458
Santa Clara 420
Seattle 304
Wilmington 255
Cambridge 231
Serra 218
Shanghai 192
Sofia 187
Beijing 174
New York 145
Milan 143
Los Angeles 116
Boardman 114
Munich 102
Ottawa 85
Princeton 84
Lawrence 75
Medford 69
Abidjan 67
Jacksonville 62
Dong Ket 60
Des Moines 59
London 54
Dearborn 53
Pisa 51
Izmir 50
Vienna 49
Florence 47
Turku 46
Hefei 44
Frankfurt am Main 42
Buffalo 38
Nanjing 38
Rome 37
Istanbul 35
Tokyo 33
Seoul 32
Ogden 31
São Paulo 31
Redondo Beach 30
Boulder 29
Brussels 27
Columbus 27
Düsseldorf 27
San Diego 27
The Dalles 27
Falls Church 24
Fuzhou 24
Lagos 24
Bremen 23
Nanchang 23
Helsinki 22
Ho Chi Minh City 21
Bern 20
Warsaw 20
Marseille 19
Dakar 18
Lucca 18
Redwood City 18
Council Bluffs 17
Pune 16
Nürnberg 14
Phoenix 13
Quanzhou 13
Shenyang 13
Hanoi 12
Lancaster 12
Montreal 12
Rho 12
Stockholm 12
Boston 11
Denver 11
Hebei 11
Kunming 11
Norwalk 11
Vicopisano 11
Jüchen 10
Nuremberg 10
Seacroft 10
Toronto 10
Guangzhou 9
Rio de Janeiro 9
Auburn Hills 8
Belo Horizonte 8
Tashkent 8
Atlanta 7
Brooklyn 7
Dülmen 7
Hangzhou 7
Jiaxing 7
Mumbai 7
Sezze 7
Totale 9.802
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 381
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 276
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 252
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 242
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 237
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 229
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 225
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 222
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 220
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 218
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 217
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 213
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 213
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 210
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 204
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 203
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 190
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 189
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 188
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 188
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 183
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 181
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 180
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 175
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 163
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 162
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 160
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 159
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 157
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 155
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 154
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 153
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 152
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 151
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 149
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 148
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 143
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 142
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 138
Prevention of capecitabine toxicity using a 5-FU test dose 137
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 137
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 137
Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation 136
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 136
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 136
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 135
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 133
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. 132
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 132
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 130
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 129
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report 128
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) 128
null 127
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 125
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 124
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 124
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 123
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 123
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation 120
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 116
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer 116
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 115
null 114
null 114
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue 113
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis. 113
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 111
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids 110
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 110
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 110
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach 108
null 101
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma 101
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma 100
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) 100
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients 98
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer 96
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 95
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients 95
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 94
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 93
Polimorfismi genetici del VEGF e DMLE 93
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase 90
null 89
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases 88
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 85
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 77
null 76
Metronomic Chemotherapy in Elderly Patients 74
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 62
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 53
null 46
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities 21
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway 21
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells 20
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo 18
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway 12
Totale 13.502
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021507 0 0 0 0 0 35 30 92 96 82 51 121
2021/2022917 14 71 21 32 154 154 26 34 53 40 54 264
2022/20231.467 175 223 126 128 158 187 9 104 259 6 80 12
2023/2024850 82 97 93 56 101 167 26 48 18 22 53 87
2024/20252.993 17 114 43 192 302 325 228 126 302 390 331 623
2025/20262.004 285 410 503 335 412 59 0 0 0 0 0 0
Totale 13.502